Search
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively. … Linaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation.[A260286]
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis … , marketed by Astellas under the brand Cresemba.
Hexobendine
go.drugbank.com/drugs/DB13265ApprovedIt has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478]. … Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris.
Cycloserine
go.drugbank.com/drugs/DB00260ApprovedInvestigationalAntibiotic substance produced by Streptomyces garyphalus.
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Asparaginase Escherichia coli
go.drugbank.com/drugs/DB00023ApprovedInvestigationalTherapeutic L-asparaginase from _E. coli_ works by depleting the levels of non-essential amino acid, asparagine, in lymphoblastic leukemic cells thus promoting apoptotic cell death [A31999]. … For patients who develop hypersensitivity to _E. coli_-derived formulations of L-asparaginase, the use of PEGylated or non-PEGylated [DB08886] is recommended [A31999].
Halofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnIt appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. … Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
Insulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigational[L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in … [L51078]The US FDA subsequently approved insulin icodec in March 2026 for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [L56102]
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedDasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Approved in December 2014 by the FDA, Viekira Pak is indicated for the treatment of HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] [FDA Label].
Synonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamideCategories: Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor